Arena Pharmaceuticals, Inc. (ARNA) to Post Q1 2018 Earnings of ($0.72) Per Share, Leerink Swann Forecasts
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) – Leerink Swann issued their Q1 2018 earnings per share estimates for Arena Pharmaceuticals in a research note issued on Wednesday. Leerink Swann analyst J. Schwartz expects that the biopharmaceutical company will post earnings of ($0.72) per share for the quarter. Leerink Swann currently has a “Positive” rating and a $56.00 price target on the stock. Leerink Swann also issued estimates for Arena Pharmaceuticals’ Q2 2018 earnings at ($0.72) EPS, Q3 2018 earnings at ($0.74) EPS, Q4 2018 earnings at ($0.74) EPS, FY2019 earnings at ($3.05) EPS and FY2020 earnings at ($3.43) EPS.
Several other equities analysts have also commented on the company. BidaskClub raised Arena Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 2nd. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $37.00 price target on shares of Arena Pharmaceuticals in a research note on Monday, September 25th. Wells Fargo & Co raised Arena Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Wednesday, January 3rd. Credit Suisse Group initiated coverage on Arena Pharmaceuticals in a research note on Wednesday. They issued an “outperform” rating and a $44.00 price target on the stock. Finally, Zacks Investment Research lowered Arena Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, January 10th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $38.38.
Arena Pharmaceuticals (NASDAQ:ARNA) last announced its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.65) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.66) by $0.01. Arena Pharmaceuticals had a negative return on equity of 34.12% and a negative net margin of 36.78%. The business had revenue of $7.95 million for the quarter, compared to analyst estimates of $5.48 million. During the same quarter in the prior year, the company posted ($0.05) EPS. The company’s quarterly revenue was down 58.6% on a year-over-year basis.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Point72 Asset Management L.P. acquired a new position in Arena Pharmaceuticals during the 3rd quarter worth about $9,973,000. American Century Companies Inc. lifted its stake in Arena Pharmaceuticals by 171.8% during the 3rd quarter. American Century Companies Inc. now owns 64,994 shares of the biopharmaceutical company’s stock worth $1,657,000 after acquiring an additional 41,082 shares in the last quarter. Swiss National Bank lifted its stake in Arena Pharmaceuticals by 30.3% during the 3rd quarter. Swiss National Bank now owns 63,630 shares of the biopharmaceutical company’s stock worth $1,623,000 after acquiring an additional 14,800 shares in the last quarter. ClariVest Asset Management LLC acquired a new position in Arena Pharmaceuticals during the 3rd quarter worth about $2,156,000. Finally, American International Group Inc. lifted its stake in Arena Pharmaceuticals by 31.2% during the 3rd quarter. American International Group Inc. now owns 26,081 shares of the biopharmaceutical company’s stock worth $665,000 after acquiring an additional 6,208 shares in the last quarter. 72.82% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: This report was first posted by Watch List News and is the property of of Watch List News. If you are accessing this report on another publication, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The legal version of this report can be read at https://www.watchlistnews.com/arena-pharmaceuticals-inc-arna-to-post-q1-2018-earnings-of-0-72-per-share-leerink-swann-forecasts/1813902.html.
Arena Pharmaceuticals Company Profile
Arena Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas. The Company has three primary investigational clinical programs: etrasimod (APD334) in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the treatment of pain associated with Crohn’s disease, and ralinepag (APD811) in Phase II evaluation for pulmonary arterial hypertension (PAH).
Receive News & Ratings for Arena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.